Kater, A. P. Et Al. 2024. Activity of venetoclax in patients with relapsed or refractory chronic lymphocytic leukaemia: analysis of the VENICE-1 multicentre, open-label, single-arm, phase 3b trial. The Lancet Oncology , vol.25, no.4 , 463-473.

Kater, A. P., ARSLAN, Ö., Demirkan, F., Herishanu, Y., Ferhanoglu, B., Diaz, M. G., ... Leber, B.(2024). Activity of venetoclax in patients with relapsed or refractory chronic lymphocytic leukaemia: analysis of the VENICE-1 multicentre, open-label, single-arm, phase 3b trial. The Lancet Oncology , vol.25, no.4, 463-473.

Kater, Arnon Et Al. "Activity of venetoclax in patients with relapsed or refractory chronic lymphocytic leukaemia: analysis of the VENICE-1 multicentre, open-label, single-arm, phase 3b trial," The Lancet Oncology , vol.25, no.4, 463-473, 2024

Kater, Arnon P. Et Al. "Activity of venetoclax in patients with relapsed or refractory chronic lymphocytic leukaemia: analysis of the VENICE-1 multicentre, open-label, single-arm, phase 3b trial." The Lancet Oncology , vol.25, no.4, pp.463-473, 2024

Kater, A. P. Et Al. (2024) . "Activity of venetoclax in patients with relapsed or refractory chronic lymphocytic leukaemia: analysis of the VENICE-1 multicentre, open-label, single-arm, phase 3b trial." The Lancet Oncology , vol.25, no.4, pp.463-473.

@article{article, author={Arnon P Kater Et Al. }, title={Activity of venetoclax in patients with relapsed or refractory chronic lymphocytic leukaemia: analysis of the VENICE-1 multicentre, open-label, single-arm, phase 3b trial}, journal={The Lancet Oncology}, year=2024, pages={463-473} }